These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 25845263

  • 1. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
    Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
    [Abstract] [Full Text] [Related]

  • 2. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
    Briganti V, Cuccurullo V, Di Stasio GD, Mansi L.
    Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
    Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [Abstract] [Full Text] [Related]

  • 5. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [Abstract] [Full Text] [Related]

  • 6. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016 May; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 11. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.
    Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC.
    J Nucl Med; 2016 Jun; 57(6):872-8. PubMed ID: 26769864
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M.
    Hell J Nucl Med; 2023 Jul; 26 Suppl():19-20. PubMed ID: 37658556
    [Abstract] [Full Text] [Related]

  • 16. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
    Pepe G, Bombardieri E, Lorenzoni A, Chiti A.
    PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
    [Abstract] [Full Text] [Related]

  • 17. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.
    J Clin Oncol; 2016 Feb 20; 34(6):588-96. PubMed ID: 26712231
    [Abstract] [Full Text] [Related]

  • 18. Other PET tracers for neuroendocrine tumors.
    Koopmans KP, Glaudemans AW.
    PET Clin; 2014 Jan 20; 9(1):57-62. PubMed ID: 25029934
    [Abstract] [Full Text] [Related]

  • 19. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
    Ambrosini V, Tomassetti P, Rubello D, Campana D, Nanni C, Castellucci P, Farsad M, Montini G, Al-Nahhas A, Franchi R, Fanti S.
    Nucl Med Commun; 2007 Jun 20; 28(6):473-7. PubMed ID: 17460538
    [Abstract] [Full Text] [Related]

  • 20. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.
    J Nucl Med; 2014 Nov 20; 55(11):1811-7. PubMed ID: 25315243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.